Antiproliferation effects of oridonin on HPB-ALL cells and its mechanisms of action

American Journal of Hematology

Volumn 81, Issue 2, 2006, Pages 86-94

  Liu, Jia Jun ^a   Huang, Ren Wei ^a   Lin, Dong Jun ^a   Wu, Xiang Yuan ^a   Peng, Jun ^b   Pan, Xiang Lin ^b   Lin, Qu ^a   Hou, Ming ^b   Zhang, Mao Hong ^b   Chen, Feng ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; Bcl 2; Caspase 3; Mitochondrial membrane potential ( m); Oridonin

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; CASPASE 3; DITERPENOID; DNA FRAGMENT; FAS ANTIGEN; ORIDONIN; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; TRYPAN BLUE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL MEMBRANE POTENTIAL; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INCUBATION TIME; LEUKEMIA CELL; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABDOSIA; STAINING; STATISTICAL ANALYSIS; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASE 3; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DITERPENES; DITERPENES, KAURANE; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION; HUMANS; MEMBRANE POTENTIALS; MITOCHONDRIAL MEMBRANES;

EID: 32144432114     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20524     Document Type: Article

References (41)

1. Boon H, Wong J. Botanical medicine and cancer: a review of the safety and efficacy. Expert Opin Pharmacother 2004;5:2485-2501.
2. Han QB, Li ML, Li SH, et al. Ent-kaurane diterpenoids from Isodon rubescens var. lushanensis. Chem Pharm Bull 2003; 51:790-793.
3. Zhang JX, Han QB, Zhao AH, et al. Diterpenoids from Isodon japonica. Fitoterapia 2003;74:435-438.
4. Ikezoe T, Chen SS, Tong XJ, et al. Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int J Oncol 2003;23:1187-1189.
5. Rossi D, Gaidano G. Messengers of cell death: apoptotic signaling in health and disease. Haematologica 2003;88:212-218.
6. Tsuruo T, Naito M, Tomida A, et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 2003;94:15-21.
7. Debatin KM. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother 2004;53:153-197.
8. Yinjun L, Jie J, weilai X, et al. Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP). Am J Hematol 2004;76:199-204.
9. Houston A, O'Connell J. The Fas signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol 2004;4:321-326.
10. Heiser D, Labi V, Erlacher M, et al. The Bcl-2 protein family and its role in the development of neoplastic disease. Exp Gerontol 2004; 39:1125-1135.
11. Philchenkov A, Zavelevich M, Kroczak TJ, et al. Caspases and cancer: mechanisms of inactivation and new treatment modalities. Exp Oncol 2004;26:82-97.
12. Suarez CR, Bertolone SJ, Raj AB, et al. Second malignant neoplasms in childhood acute lymphoblastic leukemia: primitive neuroectodermal tumor of the chest wall with germline p53 mutation as a second malignant neoplasm. Am J Hematol 2004;76:52-56.
13. Snyder DS, Stein AS, O'Donnell MR, et al. Philadelphia chromosome-positive acute lymphoblastic leukemia secondary to chemoradiotherapy for Ewing sarcoma. Report of two cases and concise review of the literature. Am J Hematol 2005;78:74-78.
14. Nicot C. Current views in HTLV-I-associated adult T-cell leukemia/lymphoma. Am J Hematol 2005;78:232-239.
15. Michael P. Kosty. PC-SPES: hope or hype? J Clin Oncol 2004;22:3657-3659.
16. Darzynkiewicz Z, Traganos F, Wu JM, et al. Chinese herbal mixture PC SPES in treatment of prostate cancer (review). Int J Oncol 2000;17:729-736.
17. de la Taille A, Hayek OR, Burchardt M, et al. Role of herbal compounds (PC-SPES) in hormone-refractory prostate cancer: two case reports. J Altern Complement Med 2000;6:449-451.
18. Sartippour MR, Seeram NP, Heber D, et al. Rabdosia rubescens inhibits breast cancer growth and angiogenesis. Int J Oncol 2005;26:121-127.
19. Han QB, Li RT, Li ML, et al. Ent-kauranoids from Isodon rubescens var. taihangensis. J Asian Nat Prod Res 2005;7:31-36.
20. Meade-Tollin LC, Wijeratne EM, Cooper D, et al. Oridonin and ponicidin are responsible for the antiangiogenic activity of Rabdosia rubescens, a constituent of the herbal supplement PC SPES. J Nat Prod 2004;67:2-4.
21. Liu JJ, Huang RW, Lin DJ, et al. Anti-proliferative effects of oridonin on SPC-A-1 cells and its mechanism of action. J Int Med Res 2004;32:617-625.
22. Liu JJ, Wu XY, Peng J, et al. Antiproliferation effects of oridonin on HL-60 cells. Ann Hematol 2004;83:691-695.
23. Liu JJ, Wu XY, Lu HL, et al. Inhibitory effect of oridonin on the proliferation of NB4 cells and its Mechanism. Chin German J Clin Oncol 2004;3:51-54.
24. Malugin A, Kopeckova P, Kopecek J. HPMA copolymer-bound doxorubicin induces apoptosis in human ovarian carcinoma cells by a Fas-independent pathway. Mol Pharm 2004;1: 174-182.
25. Bergeron S, Beauchemin M, Bertrand R. Camptothecin- and etoposide-induced apoptosis in human leukemia cells is independent of cell death receptor-3 and -4 aggregation but accelerates tumor necrosis factor-related apoptosis-inducing ligand-mediated cell death. Mol Cancer Ther 2004;3:1659-1669.
26. Kirkin V, Joos S, Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004;1644:229-249.
27. Wang S, Yang D, Lippman ME. Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol 2003; 30(816):133-142.
28. Manion MK, Hockenbery DM. Targeting BCL-2-related proteins in cancer therapy. Cancer Biol Ther 2003;2(Suppl):105-114.
29. Sharpe JC, Arnoult D, Youle RJ. Control of mitochondrial permeability by Bcl-2 family members. Biochim Biophys Acta 2004; 1644:107-113.
30. Donepudi M, Grutter MG. Structure and zymogen activation of caspases. Biophys Chem 2002;101:145-153.
31. Denault JB, Salvesen GS. Caspases: keys in the ignition of cell death. Chem Rev 2002;102:4489-4500.
32. Boatright KM, Salvesen GS. Caspase activation. Biochem Soc Symp 2003;70:233-242.
33. Qi SN, Yoshida A, Wang ZR, et al. GP7 can induce apoptotic DNA fragmentation of human leukemia cells through caspase-3-dependent and -independent pathways. Int J Mol Med 2004; 13:163-167.
34. Philchenkov AA. Caspases as regulators of apoptosis and other cell functions. Biochemistry 2003;68:365-376.
35. Smolewski P, Darzynkiewicz Z, Robak T. Caspase-mediated cell death in hematological malignancies: theoretical considerations, methods of assessment, and clinical implications. Leuk Lymphoma 2003;44:1089-1104.
36. Kelsen D. Chemotherapy of esophageal cancer. Semin Oncol 1984;11:159-164.
37. Hsu B. The use of herbs as anticancer agents. Am J Chin Med 1980;8:301-306.
38. Zhang TM, Shou MG, Wang MY. Antitumor effects of different combinations of oridonin, bleomycin A5 and nitrocaphane. Acta Pharmacol Sin 1986;7:457-460.
39. Gao ZG, Ye QX, Zhang TM. Synergistic effect of oridonin and cisplatin on cytotoxicity and DNA cross-link against mouse sarcoma S180 cells in culture. Acta Pharmacol Sin 1993;14: 561-564.
40. Wang MY, Lin C, Zhang TM. Effects of oridonin on DNA, RNA and protein syntheses of leukemia L 1210 cells studied by autoradiography. Acta Pharmacol Sin 1987;8:164-165.
41. Zhang CL, Wu LJ, Tashiro S, et al. Oridonin induced A375-S2 cell apoptosis via bax-regulated caspase pathway activation, dependent on the cytochrome c/caspase-9 apoptosome. J Asian Nat Prod Res 2004;6:127-138.